KNSTRN, a Poor Prognostic Biomarker, Affects the Tumor Immune Microenvironment and Immunotherapy Outcomes in Pan-Cancer

Figure 3

Pan-cancer analysis of KNSTRN expression in tumor cells. (a–l) Immunohistochemical analysis of KNSTRN in tissues of breast cancer, cervical cancer, colorectal cancer, testis cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, urothelial cancer, stomach cancer, liver cancer, and corresponding normal tissues. (m–o) The expression of KNSTRN in acute erythroid leukemia cell (HEL), osteosarcoma cell (U-2 OS), and astrocytoma cell (U-251 MG) by using Immunofluorescence assay.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)